Olema Pharmaceuticals Stock Performance
| OLMA Stock | USD 24.57 1.53 5.86% |
Olema Pharmaceuticals holds a performance score of 11 on a scale of zero to a hundred. The company holds a Beta of -3.77, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Olema Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Olema Pharmaceuticals is expected to outperform it. Use Olema Pharmaceuticals information ratio, value at risk, kurtosis, as well as the relationship between the sortino ratio and semi variance , to analyze future returns on Olema Pharmaceuticals.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Olema Pharmaceuticals are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak primary indicators, Olema Pharmaceuticals sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (5.86) | Five Day Return (5.68) | Year To Date Return (2.81) | Ten Year Return (49.86) | All Time Return (49.86) |
1 | Olema Oncology Announces Pricing of 190.0 Million Public Offering of Common Stock | 11/19/2025 |
2 | Disposition of 35868 shares by Rappaport Andrew of Olema Pharmaceuticals subject to Rule 16b-3 | 11/25/2025 |
3 | Disposition of 75000 shares by Kovacs Shane William Charles of Olema Pharmaceuticals subject to Rule 16b-3 | 12/08/2025 |
4 | Olema Pharmaceuticals Sets New Standards In Oncology | 12/10/2025 |
5 | Disposition of 12921 shares by Zojwalla Naseem of Olema Pharmaceuticals at 28.93 subject to Rule 16b-3 | 12/19/2025 |
6 | Disposition of 100000 shares by Zojwalla Naseem of Olema Pharmaceuticals at 28.04 subject to Rule 16b-3 | 12/22/2025 |
7 | Olema Pharmaceuticals Director Ian Clark Sells 264,800 Shares of Stock | 12/24/2025 |
8 | Disposition of 8500 shares by Bohen Sean of Olema Pharmaceuticals subject to Rule 16b-3 | 12/26/2025 |
9 | Olema Oncology prices 190.0 million public offering of common stock - MSN | 01/02/2026 |
10 | UBS initiates Olema Pharmaceuticals stock with Buy rating, 45 target - Investing.com | 01/06/2026 |
11 | Olema Insider Sells 8 Million in Shares After 300 percent Stock Surge | 01/09/2026 |
12 | Disposition of 10000 shares by David Myles of Olema Pharmaceuticals at 28.34 subject to Rule 16b-3 | 01/12/2026 |
13 | Disposition of 50000 shares by David Myles of Olema Pharmaceuticals at 4.87 subject to Rule 16b-3 | 01/13/2026 |
14 | Olema Pharmaceuticals director Harmon sells 101k in stock - Investing.com | 01/16/2026 |
15 | Disposition of 10000 shares by Cyrus Harmon of Olema Pharmaceuticals at 26.88 subject to Rule 16b-3 | 01/20/2026 |
16 | Olema Pharmaceuticals Director Sells 101,599.68 in Stock | 01/23/2026 |
| Begin Period Cash Flow | 68.5 M | |
| Total Cashflows From Investing Activities | -93.5 M |
Olema Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 897.00 in Olema Pharmaceuticals on October 31, 2025 and sell it today you would earn a total of 1,560 from holding Olema Pharmaceuticals or generate 173.91% return on investment over 90 days. Olema Pharmaceuticals is currently generating 2.5929% in daily expected returns and assumes 18.0927% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Olema, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Olema Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Olema Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 24.57 | 90 days | 24.57 | about 38.78 |
Based on a normal probability distribution, the odds of Olema Pharmaceuticals to move above the current price in 90 days from now is about 38.78 (This Olema Pharmaceuticals probability density function shows the probability of Olema Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Olema Pharmaceuticals has a beta of -3.77. This indicates as returns on its benchmark rise, returns on holding Olema Pharmaceuticals are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Olema Pharmaceuticals is expected to outperform its benchmark. In addition to that Olema Pharmaceuticals has an alpha of 2.7946, implying that it can generate a 2.79 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Olema Pharmaceuticals Price Density |
| Price |
Predictive Modules for Olema Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Olema Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Olema Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Olema Pharmaceuticals is not an exception. The market had few large corrections towards the Olema Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Olema Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Olema Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.79 | |
β | Beta against Dow Jones | -3.77 | |
σ | Overall volatility | 8.84 | |
Ir | Information ratio | 0.14 |
Olema Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Olema Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Olema Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Olema Pharmaceuticals is way too risky over 90 days horizon | |
| Olema Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Olema Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (129.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Olema Pharmaceuticals currently holds about 240.71 M in cash with (104.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01. | |
| Olema Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Olema Pharmaceuticals Director Sells 101,599.68 in Stock |
Olema Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Olema Stock often depends not only on the future outlook of the current and potential Olema Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Olema Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 58.7 M | |
| Cash And Short Term Investments | 434.1 M |
Olema Pharmaceuticals Fundamentals Growth
Olema Stock prices reflect investors' perceptions of the future prospects and financial health of Olema Pharmaceuticals, and Olema Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Olema Stock performance.
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 1.64 B | ||||
| Shares Outstanding | 80.16 M | ||||
| Price To Book | 6.40 X | ||||
| EBITDA | (141.87 M) | ||||
| Net Income | (129.47 M) | ||||
| Cash And Equivalents | 240.71 M | ||||
| Cash Per Share | 6.01 X | ||||
| Total Debt | 1.43 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 19.75 X | ||||
| Book Value Per Share | 4.48 X | ||||
| Cash Flow From Operations | (104.35 M) | ||||
| Earnings Per Share | (1.76) X | ||||
| Market Capitalization | 1.97 B | ||||
| Total Asset | 450.98 M | ||||
| Retained Earnings | (435.11 M) | ||||
| Working Capital | 396.71 M | ||||
About Olema Pharmaceuticals Performance
By analyzing Olema Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Olema Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Olema Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Olema Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.26) | (0.27) | |
| Return On Capital Employed | (0.40) | (0.38) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.36) | (0.35) |
Things to note about Olema Pharmaceuticals performance evaluation
Checking the ongoing alerts about Olema Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Olema Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Olema Pharmaceuticals is way too risky over 90 days horizon | |
| Olema Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Olema Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (129.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Olema Pharmaceuticals currently holds about 240.71 M in cash with (104.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01. | |
| Olema Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Olema Pharmaceuticals Director Sells 101,599.68 in Stock |
- Analyzing Olema Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Olema Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Olema Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Olema Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Olema Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Olema Pharmaceuticals' stock. These opinions can provide insight into Olema Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Olema Stock analysis
When running Olema Pharmaceuticals' price analysis, check to measure Olema Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Olema Pharmaceuticals is operating at the current time. Most of Olema Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Olema Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Olema Pharmaceuticals' price. Additionally, you may evaluate how the addition of Olema Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |